Zusammenfassung
Die kutanen Lymphome stellen eine heterogene Gruppe von klonal expandierenden T- und B-Lymphozyten mit unterschiedlicher klinischer Manifestation und Prognose dar. Die neue EORTC-WHO-Klassifikation kutaner T- und B-Zell-Lymphome stellt dem Kliniker eine einheitliche Nomenklatur kutaner Lymphome nach klinischen, histo- und zytomorphologischen wie auch molekularbiologischen Erkenntnissen zur Verfügung, die eine Voraussetzung für einheitliche Therapiekonzepte darstellt. Für den klinisch tätigen Dermatologen beziehen sich mehr als 50% der Therapien auf die klassischen Formen der kutanen T-Zell-Lymphome vom Typ der Mycosis fungoides. In den letzten Jahren wurde ein Paradigmenwechsel in der Therapie kutaner T-Zell-Lymphome vollzogen. Dieser beruht auf der Erkenntnis, dass frühe aggressive Therapien mit Zytostatika die Ansprechrate und das Gesamtüberleben nicht verbessern. Heute wird – allgemein akzeptiert – eine stadienadaptierte Therapie empfohlen. In der nachfolgenden Übersicht wird der derzeitige Stand der Therapie kutaner Lymphome ausführlich dargestellt.
Abstract
Cutaneous lymphomas are a heterogenous group of clonal proliferations of T and B lymphocytes with various clinical manifestations and prognosis. The new EORTC WHO classification of cutaneous T- and B-cell lymphomas provides a uniform nomenclature based on clinical, histologic, cytologic and molecular biological features. Accurate classification is a prerequisite for uniform therapeutic concepts. For office-based dermatologist, more than 50% of the therapies deal with classic forms of cutaneous T-cell lymphomas, type mycosis fungoides. In recent years the paradigm for the therapy of cutaneous T-cell lymphomas has changed. Since early aggressive treatment with cytostatic agents does not increase the response rate or overall survival, a commonly accepted stage-adapted therapy is recommended. In this review the current status of the therapy of cutaneous lymphoma is described in detail.
Literatur
Bunn PA Jr, Hoffann SJ, Norris D et al. (1994) Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome). Ann Intern Med 121: 592–602
Dummer R (2005) Emerging drugs in cutaneous T-cell lymphomas. Expert Opin 10: 381–392
Dummer R, Kempf W, Hess Schmid M et al. (2003) Therapy of cutaneous lymphoma – current practice an future development. Onkologie 26: 366–72
Dummer R, Stadler R, Sterry W (2005) Deutsche Leitlinie: Kutane Lymphome. In: Garbe C (Hrsg) Interdisziplinäre Leitlinien zur Diagnostik und Behandlung von Hauttumoren. Georg Thieme, Stuttgart, S 83–95
Duvic M, Hymes K, Heald P et al. (2001) Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational Phase II-III trial results. J Clin Oncol 19: 2456–2471
Faderl S, Coutre S, Byrd JC et al. (2005) The evolving role of alemtuzumab in management of patients with CLL. Leukemia 19: 2147–2152
Farol LT, Hymes KB (2004) Bexarotene: a clinical review. Expert Rev Anticancer Ther 4: 180–188
Foss F (2003) Overview of cutaneous T-cell lymphoma: prognostic factors and novel therapeutic approaches. Leuk Lymph 44 [Suppl 3]: S55–61
Foss F, Demierre MF, DiVenuti G (2005) A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 106: 454–457
Jacobs SA, Foon KA (2005) Monoclonal antibody therapy of leukemias and lymphomas. Expert Opin Biol Ther 5: 1225–1243
Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) Pathology and genetics of tumours of haematopoietic and lymphoid tissue. IARC Press, Lyon
Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1: 287–299
Kaye FJ, Bunn PA Jr, Steinberg SM et al. (1989) A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 321: 1784–1790
Kim EJ, Hess S, Richardson SK et al. (2005) Immunopathogenesis and therapy of cutaneous T-cell lymphoma. J Clin Invest 115: 798–812
Knobler R, Girardi M (2001) Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphomas. Ann NY Acad Sci 94: 123–138
Olsen E, Duvic M, Frankel A et al. (2001) Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 19: 376–388
Piekarz RL, Robey R, Sandor V et al. (2001) Inhibitor of histone deacetylation, depsipeptide (FR901288), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98: 2865–2868
Querfeld C, Rosen ST, Kuzel TM et al. (2005) Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy. Arch Dermatol 141: 305–311
Rupoli S, Goteri G, Pulini S et al. (2005) Long-term experience with low-dose interferon-α and PUVA in the management of early mycosis fungoides. Eur J Haematol 75: 136–145
Schon MP, Schon M (2004) Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod. Apoptosis 9: 291–298
Stadler R (1998) Interferons in dermatology – present-day standard. Dermatol Clin 16: 377–398
Stadler R, Kremer A (2006) Therapeutic advances in cutaneous T-cell lymphoma (CTCL): from retinoids to rexinoids. Semin Oncol 33 [1 Suppl 3]: S7–10
Stadler R, Otte HG (1997) Aktuelle Behandlungsstrategien kutaner Lymphome. Zeitschr Hautk H+G 72: 257–262
Stadler R, Otte HG, Luger T et al. (1998) Prospective randomized multicenter clinical trial on the use of interferon α-2a plus acitretin versus intferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma, stages I and II. Blood 92: 3578–3581
Trautinger F, Knobler R, Willemze R et al. (2006) EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. Eur J Cancer 42: 1014–1030
Urosevic M, Dummer R, Contrad C et al. (2005) Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod. J Nat Cancer Inst 15: 1143–1153
van Dognen JJ, Langerak AW, Bruggemann M et al. (2003) Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98–3936. Leukemia 17: 2257–2317
Vonderheid EC, Berengo MG, Burg G et al. (2002) Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 46: 95–106
Willemze R, Jaffe ES, Burg G et al. (2005) WHO-EORTC classification for cutaneous lymphomas. Blood 105: 3768–3785
Willemze R, Kerl H, Sterry W et al. (1997) EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of th European Organization for Research and Treatment of Cancer. Blood 90: 354–371
Wollina U, Dummer R, Brockmeyer NH et al. (2003) Multicenter study of pegylated liposomal docorubicin in patients with cutaneous T-cell lymphoma. Cancer 98: 993–1001
Interessenkonflikt
Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stadler, R. Kutane Lymphome. Hautarzt 57, 744–755 (2006). https://doi.org/10.1007/s00105-006-1189-5
Issue Date:
DOI: https://doi.org/10.1007/s00105-006-1189-5
Schlüsselwörter
- Kutane T- und B-Zell-Lymphome
- Gesamtüberleben
- Klassifikation
- Mycosis fungoides
- Stadienadaptierte Therapie